Link between e-cigarette use and early age of asthma onset in US adults found through UTHealth Houston research
IMAGE:
ADRIANA PÉREZ, PHD, MS, PROFESSOR OF BIOSTATISTICS AND DATA SCIENCE AT UTHEALTH HOUSTON SCHOOL OF PUBLIC HEALTH, FOUND A CONNECTION BETWEEN THE USE OF ELECTRONIC CIGARETTES AND EARLIER AGE OF ASTHMA ONSET.
view moreCREDIT: UTHEALTH HOUSTON
A significant link between the use of electronic cigarettes and earlier age of asthma onset in U.S. adults was reported by UTHealth Houston researchers May 17, 2024 in the Journal of the American Medical Association (JAMA) Network Open.
Led by first author Adriana Pérez, PhD, MS, professor of biostatistics and data science at UTHealth Houston School of Public Health, the research found that adults who were asthma-free at the beginning of the study and reported e-cigarette use in the past 30 days increased their risk of developing earlier age of asthma onset by 252%.
“While previous studies have reported that e-cigarette use increases the risk of asthma, our study was the first to examine the age of asthma onset,” said Pérez, who is also with the Michael and Susan Dell Center for Healthy Living at the School of Public Health. “Measuring the potential risk of earlier age of asthma onset as it relates to past 30-day e-cigarette use may help people from starting use or motivate them to stop.”
The study team analyzed secondary data from the Population Assessment of Tobacco and Health Study, a national longitudinal study of tobacco use and how it affects the health of adults and youths in the U.S.
“The findings of the study underscore the need for further research, particularly regarding the impact of e-cigarette use on youth and its association with early age of asthma onset and other respiratory conditions,” Pérez said. “It also highlights the importance of modifying screening guidelines to incorporate recent use of e-cigarettes, which could lead to earlier detection and treatment of asthma, reducing the morbidity and mortality associated with the disease.”
Pérez said the study highlights the need to address the health burden of asthma, which results in $300 billion in annual losses due to missed school or workdays, mortality, and medical costs according to the Centers for Disease Control and Prevention. Tobacco regulations, prevention, intervention campaigns, and cessation programs are needed to prevent early age of asthma onset due to e-cigarette use, the authors wrote.
Melissa B. Harrell, PhD, MPH, professor of epidemiology at the school, was senior author. Co-authors from UTHealth Houston included Pushan P. Jani, MD, MSc, associate professor of pulmonology in the Department of Internal Medicine at McGovern Medical School at UTHealth Houston, and Sarah Valencia, MS, statistician at the Michael and Susan Dell Center for Healthy Living.
JOURNAL
JAMA Network Open
METHOD OF RESEARCH
Data/statistical analysis
SUBJECT OF RESEARCH
People
ARTICLE TITLE
Use of Electronic Nicotine Delivery Systems and Age of Asthma Onset Among US Adults and Youths
ARTICLE PUBLICATION DATE
17-May-2024
COI STATEMENT
Dr Harrell reported receiving personal fees from the state of Minnesota for serving as an expert witness in litigation that the state of Minnesota brought against JUUL and Altria outside the submitted work. No other disclosures were reported.
First US trial of varenicline for e-cigarette cessation shows positive results
IMAGE:
DRS. BENJAMIN TOLL, LISA FUCITO AND COLLEAGUES DEVELOPED A STUDY TO MIMIC REAL-WORLD CONDITIONS OF PEOPLE TRYING TO STOP USING E-CIGARETTES BY USING VARENICLINE.
view moreCREDIT: LISA FUCITO
The first U.S. trial of varenicline for e-cigarette cessation shows promising results and warrants larger-scale trials, the researchers say.
Researchers from Yale Cancer Center and MUSC Hollings Cancer Center published the results of their clinical trial of varenicline to help adults to stop using e-cigarettes in the American Journal of Preventive Medicine on May 16.
The results showed a significant disparity between the placebo group and the group receiving the medication. “We had a 15% difference in quit rates, with those in the medication group having a quit rate of 45%,” said Lisa Fucito, Ph.D., lead author and director of the Tobacco Treatment Service at the Yale Cancer Center and Smilow Cancer Hospital.
Benjamin Toll, Ph.D., director of the Tobacco Treatment Program at MUSC Health and senior author on the study, said that the researchers designed the trial to mimic real-world conditions as much as possible – from the people who enrolled in the trial to the type of support they would likely receive from primary care providers.
The publication of their results closely follows publication of a trial of cytisinicline for e-cigarette cessation. The two drugs work similarly. However, varenicline is already on the market in the U.S. in generic versions while cytisinicline has not yet received FDA approval and is not currently available for use by patients.
Varenicline, perhaps better known by the brand name Chantix, is FDA-approved to help adults to stop smoking traditional cigarettes. But, despite the growing numbers of people who use e-cigarettes, there are no approved medication options to help them to stop using e-cigarettes.
“People can get to very high levels of nicotine exposure with these e-cigarette products, and they can use them near constantly throughout the day. So, the question we all have is, ‘Can any pharmacotherapy stand up to this challenge?’” Fucito said.
It’s a question of logistics. People who smoke cigarettes have to get a cigarette from the pack and light it. It’s easy to track use. There are also natural stopping points – when the cigarette is finished, it must be snuffed out, and when the pack is used up, it must be thrown away and a new one purchased and opened before the person can smoke again. E-cigarettes, however, can last for 5,000 or more puffs, making them harder to track intake but easier to use. Toll said he has patients who describe keeping their e-cigarettes under their pillows so they can vape right before going to sleep and then again immediately upon waking in the morning.
Previous studies have shown that a majority of people using e-cigarettes want to quit. But it’s been unclear whether products used to stop smoking traditional combustible cigarettes would also work for e-cigarettes.
“We need more pharmacotherapy treatments to help address the really strong physical dependence that can develop from e-cigarette use. People undergo significant withdrawal when they try to stop, and that withdrawal is so unpleasant and hard to manage with just behavioral support alone,” Fucito said.
A recent Italian study married pharmacotherapy with intense weekly behavioral counseling sessions, and the trial of cytisinicline also included weekly 10-minute sessions with trained counselors
In this study, however, the researchers wanted to see how well the pharmacotherapy could work given typical health care conditions – meaning, the patient would likely get a brief discussion with a primary care provider along with a prescription and information about resources for quitting but no follow-up counseling sessions.
To recreate this, they developed a self-guided cessation booklet for patients, with practical tools and tips for quitting. A licensed health care provider also met with each patient to inform them of how to use the medication, offer brief advice and instruct them to set a quit date for one to two weeks after starting the medication.
“We took a much lighter touch to reflect the behavioral support that you’d likely experience if you went to your doctor and asked for help with quitting e-cigarettes,” Fucito said.
The study also included some patients with histories of depression. This was significant because Chantix, at one point, had a “black box warning” after reports linking the drug to psychiatric side effects. That warning was dropped in 2016 after a very large study showed the drug to be safe, but Toll and Fucito said the stigma of the warning remains in the minds of both health care providers and the general public.
“There’s still some hesitancy to prescribe this very safe – now generic – drug, and it really shouldn't be that way,” Toll said.
None of the participants in this study experienced serious side effects, although a larger study would be needed to verify this finding. Most of the side effects were along the lines of nausea, insomnia or vivid dreams.
Another piece of good news – those who stopped vaping didn’t boomerang back to cigarettes.
“If you have a former smoking history, one of the worries in the field is that you’re going to go back to smoking when you quit vaping,” Toll said. “And we did not find that.”
On the other hand, one potential challenge that the researchers uncovered in the results indicated that people without a cigarette smoking history – in other words, those who have only ever used e-cigarettes – might have a harder time quitting. That could be because that group is more likely to use e-cigarettes continuously throughout the day, therefore getting more nicotine into their systems.
Larger trials are needed to delve into these questions. But this trial, at least, should give health care providers some confidence in prescribing varenicline for patients trying to stop using e-cigarettes.
“We want people to come back to this medication,” Fucito explained. “There are people who need help now and are likely to struggle to quit e-cigarettes on their own because the technology facilitates nicotine use on a level that we’ve never seen before.”
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
###
About the Yale Department of Psychiatry
The Yale Department of Psychiatry is a world leader in patient care, research, and education. The department prides itself on its diverse and talented faculty, including a cadre of compassionate clinicians, interdisciplinary teams of talented investigators, and numerous committed and dedicated teachers, as well as a network of able alumni that remain vital to its missions. The department not only provides the highest quality of patient care, but also leads the nation in discoveries that are transforming our understanding and treatment of mental illness and addiction.
About MUSC Hollings Cancer Center
MUSC Hollings Cancer Center is South Carolina’s only National Cancer Institute-designated cancer center with the largest academic-based cancer research program in the state. The cancer center comprises more than 140 faculty cancer scientists and 20 academic departments. It has an annual research funding portfolio of more than $50 million and sponsors more than 200 clinical trials across the state. Dedicated to preventing and reducing the cancer burden statewide, the Hollings Office of Community Outreach and Engagement works with community organizations to bring cancer education and prevention information to affected populations. Hollings offers state-of-the-art cancer screening, diagnostic capabilities, therapies and surgical techniques within its multidisciplinary clinics. Hollings specialists include surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, psychologists and other clinical providers equipped to provide the full range of cancer care. For more information, visit hollingscancercenter.musc.edu.
JOURNAL
American Journal of Preventive Medicine
ARTICLE TITLE
Varenicline for E-Cigarette Cessation in Adults: A Preliminary Placebo-Controlled Randomized Trial
ARTICLE PUBLICATION DATE
16-May-2024
COI STATEMENT
Unrelated to this study, authors report the following financial disclosures. Dr. Fucito has received funding from Imbrium Therapeutics, LLC for serving on an advisory board. Dr. Toll has testified on behalf of plaintiffs who have filed litigation against the tobacco industry. Dr. Gray has provided consultation to Indivior and Jazz Pharmaceuticals and has received research support from Aelis Farma. Dr. O'Malley has been a member of the Alcohol Clinical Trials Initiative (ACTIVE) Workgroup, which has been supported by Alkermes, Dicerna, Beam Diagnostics, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. She has been a consultant to Dicerna, received medication supplies from Novartis/Stalicla, and is an inventor on a patent application with Yale and Novartis. Dr. Krishnan-Sarin has received free medication supplies from Novartis/Stalicla for investigations on alcohol drinking behaviors. SRB, NLB, AMP, and MJC have no financial disclosures to report.
